NEW YORK, Dec. 11, 2024 /PRNewswire/ — A2A Pharmaceuticals, Inc. (“A2A or “the company”), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today announced significant progress in its clinical studies exploring TACC3 (Transforming…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.